Internal Medicine, Hematology & Oncology · Dothan, AL
NPI
1720170053
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
287 Healthwest Dr
Dothan, AL, 36303
Phone (334) 792-9500
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.4M
254,954 services
Medicare patients, 2024
878
Average age 75
Drug cost, 2024
$6.6M
1,799 prescriptions
Company payments, 2025
$22K
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael S McAllister was code J0185 (injection, aprepitant, 1 mg), 26,000 times for 55 patients. In total Michael S McAllister billed 254,954 services in 118 codes, and Medicare paid $4.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 26,000 | 55 | $1.33 | $35K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 21,000 | 27 | $43.41 | $912K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 17,250 | 16 | $0.88 | $15K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 16,100 | 46 | $4.34 | $70K |
| J0897 Injection, denosumab, 1 mg | Office | 11,640 | 106 | $19.77 | $230K |
| J9267 Injection, paclitaxel, 1 mg | Office | 10,426 | 16 | $0.08 | $818 |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 7,050 | 15 | $45.86 | $323K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 5,176 | 90 | $0.07 | $374 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,398 | 125 | $0.09 | $388 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,168 | 11 | $21.33 | $68K |
| 85025 Blood Count | Office | 2,093 | 759 | $7.52 | $16K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 2,000 | 11 | $0.06 | $117 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 1,912 | 11 | $32.97 | $63K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,532 | 15 | $3.49 | $5,353 |
| 36415 Venipuncture Blood Collection | Office | 1,109 | 582 | $5.49 | $6,089 |
By year: 2022 $4.2M for 274,064 services; 2023 $4.0M for 291,189 services; 2024 $4.4M for 254,954 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,093 | 759 | $7.52 | $16K |
| 36415 Venipuncture Blood Collection | 1,109 | 582 | $5.49 | $6,089 |
| 80053 Clinical Chemistry | 121 | 91 | $10.23 | $1,238 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael S McAllister prescribed most often to Medicare patients was Letrozole, with 201 prescriptions and refills. In total Michael S McAllister wrote 1,799 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 201 | 482 | 61 | $4,266 |
| Aprepitant Generic | 139 | 139 | 28 | $52K |
| Anastrozole Generic | 131 | 312 | 41 | $2,695 |
| Xtandi Enzalutamide | 77 | 77 | Under 11 | $1.0M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 71 | 71 | 36 | $1,714 |
| Ibrance Palbociclib | 58 | 58 | Under 11 | $881K |
| Prochlorperazine Maleate Generic | 54 | 54 | 26 | $842 |
| Prednisone Generic | 54 | 61 | 20 | $220 |
| Ondansetron Hcl Generic | 53 | 53 | 32 | $568 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 47 | 47 | 20 | $1,075 |
| Trazimera Trastuzumab-Qyyp | 36 | 36 | Under 11 | $153K |
| Cabometyx Cabozantinib S-Malate | 35 | 35 | Under 11 | $863K |
| Dexamethasone Generic | 35 | 49 | Under 11 | $625 |
| Tamoxifen Citrate Generic | 33 | 59 | 11 | $919 |
| Tagrisso Osimertinib Mesylate | 31 | 31 | Under 11 | $500K |
Brand drugs: 524 claims; generic drugs: 1,275 claims; opioid claims: 194.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael S McAllister $22K ($22K in general payments such as food, travel and fees) from 42 companies. The largest payer was Gilead Sciences, Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 24 | $19K |
| ASD Specialty Healthcare, LLC | 4 | $314 |
| Daiichi Sankyo Inc. 4568.T | 8 | $232 |
| Incyte Corporation INCY | 4 | $230 |
| Genzyme Corporation SNY | 3 | $212 |
| BeOne Medicines USA, Inc. ONC | 5 | $205 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $161 |
| Pfizer Inc. PFE | 11 | $142 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $135 |
| Geron Corporation GERN | 2 | $120 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.